The 2026 Employer Benefits Outlook

Every January, employers are handed a number. It arrives in a renewal packet, wrapped in a few paragraphs of explanation, and it is almost always bigger than last year's. For companies between 20 and 500 employees, that number now lands with more force than ever — benefits are the second-largest line item on most payrolls, and the trend lines for 2026 do not bend in the employer's favor on their own.

But the number is not destiny. The employers who will absorb 2026 well are the ones who understand why costs are moving, where the pressure is concentrated, and which levers are actually in their control. Here is the landscape as we see it heading into the year — and what to do about it.

1. Medical trend is sticky, and it's structural

Medical cost trend — the underlying rate at which the cost of care rises before any plan changes — has settled into the high single digits to low double digits, and it is not a temporary spike. The drivers are structural: an aging covered population, hospital and provider consolidation that reduces price competition, the steady migration of care toward higher-cost specialty treatment, and a small number of catastrophic claimants who now move an entire group's experience.

For a midsize employer, that last point is the quiet killer. When you cover 150 lives, a single organ transplant, a NICU stay, or a million-dollar specialty drug course can reshape your renewal. Trend is the tide; high-cost claimants are the rogue waves — and most plans are not structured to see them coming.

2. Pharmacy — and GLP-1s specifically — is the headline story

If there is one line on your report card that deserves a second look in 2026, it is pharmacy. Specialty drugs already account for a disproportionate share of total Rx spend despite being used by a tiny fraction of members. Layered on top is the GLP-1 wave — the class of medications used for diabetes and, increasingly, weight management — which has moved from a niche cost to a board-level question.

Employers are being forced to make a genuinely hard decision: cover GLP-1s for weight management and accept a meaningful new cost, or restrict coverage and explain that choice to employees who are asking for it by name. There is no painless answer, but there is a disciplined one — and it starts with reading your pharmacy data instead of accepting it.

The employers who lose control of cost in 2026 won't lose it at the medical claim. They'll lose it in the pharmacy line they never learned to read.

3. Funding strategy is moving down-market

For decades, the assumption was simple: small and midsize companies buy fully-insured coverage, and only large employers self-fund. That line has moved. Level-funding and self-funding are now realistic — often advantageous — for groups well under 250 employees, thanks to better stop-loss markets and administrators built for smaller groups.

The appeal is twofold. First, you stop paying the insurer's risk margin and state premium tax on dollars you didn't need. Second, and more importantly, you finally get claims data — the same data the carrier has been using to price you all along. We expect the shift to accelerate in 2026 as more employers realize that staying fully-insured is, in effect, choosing to fly blind.

4. Mental health and whole-person care are now table stakes

Employee expectations have permanently reset. Access to mental health support, virtual care, and navigation help is no longer a differentiator — it is the baseline a competitive employer is expected to clear. The cost question has shifted from "should we offer this?" to "are we paying for point solutions that overlap, and can employees actually find them?"

2026 is the year to audit the stack. Many midsize employers are quietly paying for three tools that do similar things, with single-digit utilization on all of them, because each was added in a different year to solve a different fire.

5. Compliance is no longer a back-office concern

The regulatory environment has put fiduciary responsibility squarely on the employer. Recent transparency rules and the broader scrutiny of how benefits dollars are spent mean that plan sponsors are increasingly expected to demonstrate that they shopped, compared, and made prudent decisions — not just renewed by reflex.

Practically, that means staying current on prescription drug data reporting, gag-clause attestations, transparency-in-coverage requirements, and ACA affordability thresholds. None of these are optional, and the cost of getting them wrong is rising. Treat compliance as a quarterly discipline, not an annual scramble.

The three moves to make now

Forecasts are only useful if they change behavior. If you do nothing else with this outlook, do these three things before your next renewal cycle begins:

1. Get your data out of the black box. Whether through a funding change or a data-sharing arrangement, stop renewing on the carrier's summary and start working from your own claims and pharmacy experience. You cannot manage what you cannot see.
2. Put a real strategy around pharmacy. Review your PBM arrangement, understand your specialty and GLP-1 exposure, and decide your coverage posture deliberately — before the renewal forces a rushed answer.
3. Start the renewal 120+ days out. The single biggest predictor of a good renewal is time. Early process means you can market the plan, model alternatives, and negotiate from leverage instead of accepting a number under deadline pressure.

The bottom line

2026 will not be a cheap year for employer-sponsored benefits. But "expensive" and "out of control" are different things. The companies that treat their benefits program like the major financial investment it is — with data, strategy, and a calendar that starts early — will navigate the year with their costs managed and their people taken care of. The ones that wait for the renewal packet will, once again, be handed a number.